© 2026 Nanjing Finechem Holdings Co., Ltd,
All Right Reserved
If you ever spent time in a cell biology lab, chances are you’ve crossed paths with Cytochalasin B. This fungal metabolite made its way into cell biology lore after its isolation from Helminthosporium dematioideum in the late 1960s. Researchers, hungry for clues about how cells shape themselves and move, grabbed onto Cytochalasin B with enthusiasm. At its core, the compound impacted actin filaments—a feature that quickly became both a blessing and a challenge for anyone studying the skeleton of the cell. Scientists in the decades since then built experiments and hypotheses on the back of observations handled, in no small part, by Cytochalasin B, finding ways to unpick the mysteries of cytokinesis, cell motility, and more. The story of this compound is inseparable from the explosion of knowledge about cell structure and dynamics that rewrote biology textbooks.
Across the global research community, Cytochalasin B crops up under an array of product names and catalog numbers. Supply companies standardize the powder, which ranges from off-white to pale yellow, making sure researchers around the world know exactly what they're getting in each vial. The focus isn't just on purity; it's about reliability. Cell division studies, transport phenomena, and drug-resistant cancer models all depend on Cytochalasin B interrupting actin polymerization just as expected. Each step forward in biomedical research leans on the consistency of the tools brought to the lab bench.
As molecular structures go, Cytochalasin B isn’t enormous, but it’s distinctive. With the formula C29H37NO6, it dissolves in DMSO, methanol, and ethanol, but not in water, which can challenge younger researchers until they get the hang of reagent handling. It melts near human body temperature—about 184°C—and breaks down at higher heat, reminding anyone using it that gentle handling matters. The molecule’s stereochemistry, shaped like a bicyclic core adorned by a macrocyclic ring system, explains why it wedges into actin filaments and blocks their growth.
Lab-grade Cytochalasin B typically comes with a purity rating above 98%. Labels run detailed, noting purity, lot numbers, handling warnings, and expiration dates, because nobody wants to gamble with contaminated tools. Researchers scan the fine print; cell survival and data quality depend on it. Directions for storage in cool, dark conditions—ideally frozen—remind everyone that even a stable molecule can lose its punch if handled carelessly. Shelf life matters, but daily lab practice often beats the clock as experiments sap supplies faster than time does.
Making Cytochalasin B at scale never looks like backroom chemistry. Industrial fermentation with Helminthosporium or related fungi launches the process. Extraction then calls for solvents like chloroform, and further purification brings out the fine needles of Cytochalasin B that biologists recognize. Modern prep depends on chromatography to weed out closely related impurities—essential, because even slight contamination can cloud research conclusions. Purification isn’t just a box-ticking task in manufacturing; it’s the daily reality of product managers and bench scientists responsible for supply quality.
Cytochalasin B’s chemical flexibility gives chemists room to tweak its structure for new purposes. The reactive sites on the molecule—particularly the side chains and the cyclohexanone moiety—open possibilities for fluorescent labeling or bioconjugation. In research, these modifications turn a generic cytoskeleton disruptor into a marker that pinpoints actin threads under a microscope. Past decades saw experiments with derivatives exploring potency and specificity, pushing the molecule’s utility beyond the original horizon. Every change in structure gets weighed for impact on toxicity and cellular entry, since cell permeability and reactivity decide the fate of both experiments and potential therapies.
Scientists and suppliers throw around names like CB, Cytochalasin-B, and fungal cytotoxins in papers and catalogs. Depending on the region or the research field, others may refer to it as demethylmacrosporin or by experimental code numbers—yet the fingerprint of its impact on the cytoskeleton means everyone knows what’s being discussed, regardless of the label.
Cytochalasin B’s cytotoxicity is exactly what makes it valuable, but nobody in a lab forgets about gloves and eye protection. Inhalation, skin exposure, or ingestion pose risks; no one wants to find out what a cytoskeletal breakdown feels like firsthand. Regulatory advisories advise containment, proper disposal in solvent waste, and banned use outside controlled lab settings. Because trace amounts can disrupt cell physiology, contamination in communal areas or shared equipment becomes a real concern in core facilities. Training on handling and emergency protocols lies at the heart of any safe research environment where Cytochalasin B features.
Cytochalasin B reshaped cell biology’s approach to the cytoskeleton. Studies on actin dynamics, vesicular trafficking, membrane ruffling, and especially cytokinesis all build on the selective disruption the compound brings. Researchers use it to model disease mechanisms, like tumor metastasis or vascular integrity, and to probe diabetes-related glucose uptake studies. It helps cancer biology teams screen for drugs that override therapy resistance. Beyond biomedicine, agricultural researchers look at fungal toxins like Cytochalasin B as a caution tale for food safety, reminding us that every lab tool is a double-edged sword.
Research into Cytochalasin B keeps turning up new wrinkles. Novel derivatives spark interest as tools for live-cell imaging or as potential adjuncts in targeting drug-resistant tumors. Teams exploring the molecular clutch that connects cytoskeletal changes to gene expression find Cytochalasin B a constant companion, either as a disruptor or as a clue to deeper mechanisms. Some current projects focus on delivery systems, aiming for pinpoint accuracy in modulating cell morphology or motility. Every finding—whether it makes for better labels, new therapies, or streamlined protocols—draws on over half a century of expertise built up since the compound’s first isolation.
Toxicologists weighed the long-term effects of Cytochalasin B by running classic LD50 assessments and modern in vitro screens. The compound’s disruption of actin isn’t subtle, and that raises flags for any researcher tempted to take shortcuts on personal protection. Long-term animal studies point to effects on cell proliferation, organ development, and even chromosomal stability. Regulatory authorities pay attention to this data, given implications for occupational exposure and environmental impact. Any suggestion that actin-targeting drugs could leap from bench to bedside faces hard scrutiny under safety evaluation, making deeper mechanistic understanding more valuable than ever.
The world of cytoskeleton research won’t outgrow Cytochalasin B anytime soon. As gene editing, cell engineering, and synthetic biology push the frontiers, the need for precise, reliable actin modulators rises. There’s growing curiosity about repurposing Cytochalasin B derivatives as antivirals or as part of targeted cancer regimens, though the road from petri dish to patient runs through narrow passes of safety testing. Automation in R&D and shifts toward higher-throughput screening create a demand for standardized formulations. The challenge for the next wave of scientists lies in balancing the power of disruption against complexity and safety. If past decades tell any story, Cytochalasin B will keep its place in the biology toolkit, but not without new eyes searching for smarter, safer, and more specific cousins.
Researchers often look for ways to peel back the curtain on how living cells actually work, especially during cell division or when cells change shape. Cytochalasin B, a substance first isolated from mold in the 1960s, gives scientists a reliable tool to do just that. In my own biology studies, experiments with this compound taught me more about how cells handle their own internal scaffolding than any textbook. Cytochalasin B disrupts actin filaments, the tiny cables that help cells keep their shape and move things around. Cells lose their structure and become much easier to study in terms of division, movement, and how they pull apart.
Lots of drugs can interrupt cell activities, but Cytochalasin B strikes right at the heart of the cytoskeleton. It doesn’t just slow things down; it stops actin assembly cold. Scientists use this to watch cells either freeze in place or fall apart during division. For example, in cancer research, this opens doors to studying how cancer cells grow unchecked. The National Institutes of Health highlight its routine use to create aneuploid cells, which have abnormal chromosome numbers. These studies can lead to better cancer treatments or at least help screen potential drugs.
Hospitals and diagnostic labs use Cytochalasin B for more than just academic curiosity. Clinical labs exploit its ability to change cell membranes to test for certain conditions. For example, red blood cells treated with Cytochalasin B can show how sensitive those cells are to certain pathogens or diseases. Glucose transport studies in diabetes research rely on it too—since Cytochalasin B blocks glucose uptake, scientists can learn how diabetic cells respond to insulin.
The benefits sound obvious, but the risks can’t be shrugged off. Cytochalasin B is a powerful disruptor; in the wrong hands or at the wrong dose, it messes up more than just lab cell cultures. It’s classified as toxic. Anyone handling it should use gloves, safety glasses, and sometimes even respirators. Academic oversight and safety rules don’t exist just for show—I remember the stern warnings about getting even a speck on skin.
Cytochalasin B isn’t just stuck in a supporting role. Pharmaceutical companies have toyed with spin-off drugs that use its structure to create safer, targeted medications. Blocking cancer cell growth at the actin level sounds promising, but making these compounds safe enough for patients is a major hurdle. The damage they do isn’t always reversible, and human cells rely on actin for basic survival.
Cytochalasin B shows that sometimes the right chemical can answer stubborn questions in biology and medicine. People who use it push our understanding of disease forward. At the same time, regulatory bodies and ethical committees keep a close eye on protocols to keep both people and the environment safe. As with all strong lab tools, safety, respect, and a firm grasp of its risks are keys to getting the most out of its unique abilities.
Cytochalasin B doesn’t get mentioned at family dinners, but it holds a key role in labs where people study cancer, genetic diseases, and drug development. This compound, found naturally in certain fungi, takes a unique approach to cell division. Instead of directly attacking the DNA or cell nucleus, Cytochalasin B blocks the formation of actin filaments, an essential part of the cell’s inner scaffolding.
Most people picture cell division as an automatic process. One cell becomes two, the cycle repeats, and that’s the basis of every living thing growing or repairing itself. At the heart of this process is a moment where the cell squeezes in the middle and splits, a step called cytokinesis. Cytochalasin B steps in right here, putting up a roadblock. By interfering with actin, it prevents the cell membrane from drawing in and pinching off, so you end up with a big cell containing two nuclei instead of two new cells.
Back in graduate school, I saw this firsthand under the microscope. After just a brief exposure, cells ballooned and doubled their internal components, but no satisfactory split ever occurred. This phenomenon turns into a handy experimental trick. Researchers use Cytochalasin B to make cells with extra nuclei, which helps them study genetic material, cell cycle controls, and biochemical pathways that malfunction in diseases such as cancer.
Oncologists notice that cancer exploits cell division to grow faster than healthy tissue. That’s what makes Cytochalasin B stand out—it forces a reset on this fundamental process. A compound that reliably stops cells from splitting has real value as a research tool, maybe even a model for future therapy ingredients. Before anyone starts dreaming about miracle cures, there’s a practical side: Cytochalasin B doesn’t discriminate between normal and cancerous cells. It halts healthy cells, too, which drives home the complexity of safely targeting only diseased tissue.
Using Cytochalasin B outside a controlled lab sparks concerns. Any chemical that tinkers with cell structure runs the risk of harming other systems. Medical personnel and scientists keep the exposure controlled and measure the downstream effects carefully. As a scientist, I learned to keep detailed notes on every dose and keep a sharp eye out for unintended changes in cell health.
Reproducibility remains a hurdle. Different cell types respond in unique ways, and growth conditions can tip results in unexpected directions. So, rigorous controls and repeat trials underpin trustworthy findings. That ties in with the push for transparency and data sharing—pillars in modern scientific work, reinforced by groups like the NIH and journal editors who now check that experimental designs stand up to scrutiny.
More selective chemicals could hold promise for disrupting cancer growth, inspired by Cytochalasin B’s actin-blocking powers but refined for precise action. Gene editing, high-throughput screening, and 3D cell models all offer ways to test smarter compounds. Every new approach brings up cost, accessibility, and long-term safety, highlighting the need for diverse teams and robust oversight by researchers and ethics boards. Any leap forward in blocking abnormal cell division will come from persistent, open collaboration—never from a single substance or shortcut.
Researchers and lab professionals know that Cytochalasin B plays a strong role in disrupting actin filament formation, making it a go-to tool for cell biology studies. People who run labs know nothing throws off an experiment like a poorly stored reagent. Cytochalasin B wants a home in the freezer. The gold standard here is -20°C. This isn’t just a guideline on the label. Cytochalasin B degrades much faster at room temperature, and even a regular refrigerator won't cut it for long-term storage. Sticking with the -20°C freezer helps maintain its power for months, sometimes longer.
I learned long ago, after troubleshooting failed cell division assays, that ignoring storage recommendations burns time and budget. Cytochalasin B left out on the bench loses potency. Science demands consistency, so failing to control temperature means some batches turn weak, giving spotty results. For scientists, who want reproducible outcomes, such random variables break trust in their data. Cold storage, specifically at -20°C, slows down molecular breakdown, so you get the compound you paid for, not a mystery potion.
Manufacturers run quality assurance to guarantee each vial meets stated concentrations and purity right out of the box. The stories rarely end there in a real-world lab. Stuff happens—freezer doors get propped open, or the vials move to share cold space with DNA samples or enzymes. If a bottle of Cytochalasin B thaws and refreezes, clumping can occur, or sometimes invisible changes cancel its bioactivity. My practice: label vials with “Do Not Disturb” and make a note in the freezer log. It’s not about being fussy—it’s about making sure every experiment starts with good material.
Some folks split a new vial into smaller tubes (aliquots) to cut down on freeze-thaw cycles. Aliquoting reduces waste and lessens the chance of the entire stock going bad. During shipment, suppliers usually pack Cytochalasin B on dry ice, further showing just how temperature-sensitive this compound can be. After delivery, move it straight into the -20°C freezer. Avoid cycles in and out of the cold—use a cold block or insulated container for weighing out doses. Even on a busy day, taking care of these small steps pays off.
Improving chemical storage is less about upgrading equipment and more about discipline. Freezer logs, proper labeling, and clear bench rules guard expensive compounds from accidental ruin. Labs thriving for quality control often assign one team member to monitor chemical stocks and storage conditions. This creates accountability, and everyone knows who to ask if something goes wrong. Implementing temperature monitors with alarms also sends early warnings if a freezer malfunctions, stopping a meltdown before it ruins a year’s budget of reagents.
No researcher wants results that don’t hold up because the tools failed before the experiment started. Trustworthy study outcomes often start behind the scenes, in the discipline of proper storage. It’s not exciting, but consistent freezers and simple routines keep Cytochalasin B useful for quite a while, supporting good science along the way.
Cytochalasin B has a long history in research labs. Scientists value it for its ability to disrupt how cells divide and move. That means it’s turned up in studies looking at cancer, cell biology, and sometimes even in work on infectious disease. This fungal compound works by interfering with actin – the “skeleton” inside cells – so the cells can’t keep their normal shape or split.
It’s not something you’ll find in your pantry, or headed for use in food or everyday products. A lot of people never hear about this chemical outside research circles. Still, questions about its safety matter to anyone concerned about accidental exposure in science labs or future medical uses.
Cytochalasin B doesn’t just target “bad” cells; it can harm just about any animal or human cells it meets, simply because all cells have some kind of actin. Studies dating back decades report that it’s toxic in even modest doses. For example, research in rodents showed liver, kidney, and blood problems after repeated exposure. At higher doses, death came quickly. No surprise that the World Health Organization classifies this fungus as unsafe for animals and humans if swallowed, breathed in, or allowed through the skin.
Cell studies show much the same story. Typical concentrations used in lab settings (nanomolar to micromolar range) stop cells from dividing and can kill them. Cytochalasin B makes it impossible for cells to close off after division, so big, multinuclear cells pile up until they die off.
Even though cytochalasin B stays in the lab, accidents happen. Broken vials, spills, or improper waste handling give it a chance to reach skin, air, or water. Factory workers, lab techs, or even cleaning crews face higher risks than the average person, just because they work near places where the substance lives.
Another concern crops up in food safety investigations. Some fungi that grow on grains and food can make cytochalasin B along with other toxins. While most harvests in regulated countries get tested for mold and mycotoxins, the risk still exists in places where monitoring falls short. Livestock exposed through feed could end up sick, passing the impact up the food chain.
No one wants a world where a lab chemical sneaks out into wider circulation – history taught tough lessons that way with asbestos, DDT, and other compounds once considered “safe enough.” What makes cytochalasin B important isn’t just its effects in a Petri dish. People who spend time in research or near biotech plants count on solid information and careful management of risk.
From my own time working with hazardous compounds, I’ve seen accidents that could have been avoided with stronger safety rules and better training. Too many workplaces cut corners with toxic chemicals, especially once the research dollars dry up and oversight drops away. That’s why constant vigilance matters more than any single safety data sheet.
To limit harm, labs and factories need simple but strict routines: sealed containers, ultra-clean environments, personal safety equipment, and dedicated waste systems. It’s not enough to hand out safety goggles and hope for the best. Companies and institutions should repeat hazard training often and push for transparency – not just compliance – when problems are found.
Agriculture and food safety regulators should expand testing for cytochalasin toxins where infected grain or spoilage could leak into the food chain. The technology for detection exists, but it doesn’t help unless used consistently. Funding for this kind of oversight brings real returns, from healthier food systems to safer workplaces and less risk of long-term, accidental exposure.
Cytochalasin B has earned its spot on the shelf in any cell biology lab focused on actin dynamics or membrane trafficking. Despite its popularity, many scientists starting out in the field might feel confused about how much Cytochalasin B delivers the right punch without tipping a culture into chaos. Getting that dose right shapes everything downstream: cell morphology, metabolic activity, and viability.
Researchers usually reach for concentrations in the range of 1–10 μg/mL when treating mammalian cells. For tweaking the actin cytoskeleton, 2–5 μg/mL lands in the “Goldilocks zone.” At doses in this bracket, cells start showing clear changes in shape and movement, but they still stay alive long enough to generate useful data. A study from 2023 in Cellular Molecular Life Sciences reported nearly identical ranges across multiple cell types, including fibroblasts and epithelial lines.
If someone just wants to block cytokinesis and make binucleated cells (common in chromosome studies), 2–4 μg/mL does the job in most cases. Cranking up the concentration above 10 μg/mL often wipes out the culture completely, so few protocols go that high unless the whole point is to observe catastrophic cell death or rule out any actin-based processes.
In my own experience working with mouse fibroblasts, adding 1 μg/mL did little more than nudge the cells’ movement. Bumping up to 3 μg/mL brought predictable changes, like cell rounding and the development of actin clumps near the membrane. Anything over 8 μg/mL produced suspensions littered with dead cells and floating debris. Skipping the careful titration step simply wasted time and resources.
Small tweaks in concentration can flip the results, turning meaningful images into indecipherable noise. At 2 μg/mL, glucose uptake assays can pick up subtle transport differences — critical for diabetes or obesity research. Push the dose too high, and you wind up measuring how fast cells die, missing the point of most metabolic assays.
A single batch of reagent or switch between serum lots also alters how cells respond to Cytochalasin B. Scientists who skip controls or fail to check for cytotoxicity might publish results that don’t hold up when someone tries the same experiment elsewhere. This happened in our lab more than once, teaching us the value of including untreated and vehicle controls every time.
Running a pilot dose-response curve with every new batch of cells or Cytochalasin B can save labs grief in the long run. Many top-tier labs freeze small aliquots to avoid repeated freeze-thaw cycles, which erode the compound’s potency. Regular mycoplasma checks and a habit of monitoring cell density during treatment also prevent accidental overexposure.
Documentation plays a major role. Detailed recording of concentration, duration, confluency, and medium type helps ensure the work stands the test of peer review and reproducibility. Sticking to well-supported ranges, sharing protocols with colleagues, and keeping good notes go a long way to make the most of Cytochalasin B in cell culture.
| Names | |
| Preferred IUPAC name | (3S,6E,8S,9R,10E,12S,13R,14R,16R)-13,14,16-Trihydroxy-8,9-methano-3-methyl-1-oxacyclohexadeca-6,10-diene-2,5,11-trione |
| Other names |
CB Phytotoxin B NSC 209835 |
| Pronunciation | /saɪtəʊkəˈleɪsɪn biː/ |
| Identifiers | |
| CAS Number | 14930-96-2 |
| Beilstein Reference | 3564104 |
| ChEBI | CHEBI:2764 |
| ChEMBL | CHEMBL357475 |
| ChemSpider | 9860 |
| DrugBank | DB02152 |
| ECHA InfoCard | 100.194.382 |
| EC Number | 201-574-5 |
| Gmelin Reference | 56922 |
| KEGG | C01257 |
| MeSH | D003561 |
| PubChem CID | 5282217 |
| RTECS number | GF3100000 |
| UNII | C7M7B5M1V1 |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C29H37N5O5 |
| Molar mass | 479.6 g/mol |
| Appearance | White powder |
| Odor | Odorless |
| Density | 1.01 g/cm³ |
| Solubility in water | Insoluble |
| log P | 1.85 |
| Acidity (pKa) | 13.15 |
| Basicity (pKb) | 8.68 |
| Magnetic susceptibility (χ) | -4.6×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.651 |
| Viscosity | Viscous oil |
| Dipole moment | 5.75 ± 1.21 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 393.5 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | D03AX11 |
| Hazards | |
| Main hazards | May cause genetic defects. Suspected of causing cancer. Causes damage to organs. |
| GHS labelling | GHS02, GHS06, GHS08 |
| Pictograms | GHS06,GHS08 |
| Signal word | Danger |
| Hazard statements | H302: Harmful if swallowed. H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | Precautionary statements: P261, P264, P271, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P362+P364, P403+P233, P405, P501 |
| NFPA 704 (fire diamond) | 2-3-0 |
| Lethal dose or concentration | LD50 (mouse, intraperitoneal): 7.44 mg/kg |
| LD50 (median dose) | LD50 (median dose) = 10 mg/kg (Intraperitoneal, Mouse) |
| PEL (Permissible) | PEL (Permissible Exposure Limit) for Cytochalasin B: Not established |
| REL (Recommended) | 10 μM |
| Related compounds | |
| Related compounds |
Cytochalasin A Cytochalasin C Cytochalasin D Cytochalasin E |
